HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gérard Jaouen Selected Research

afimoxifene (hydroxytamoxifen)

9/2013The in vivo performance of ferrocenyl tamoxifen lipid nanocapsules in xenografted triple negative breast cancer.
1/2011Synthetic and mechanistic pathways of cis and trans-hydroxytamoxifen drug derivatives reacting with Cp*Rh complexes that involve η1-N, η2-N,O, η1-O, and η6 bonding modes, via a novel N-π rearrangement; relative binding affinities and computer docking studies of cis and trans-η6-Cp*Rh-hydroxytamoxifen complexes at the estrogen, ERα and ERβ receptors, and growth inhibition to breast cancer cells.
5/2010A ferrocenyl derivative of hydroxytamoxifen elicits an estrogen receptor-independent mechanism of action in breast cancer cell lines.
11/2006The presence of a ferrocenyl unit on an estrogenic molecule is not always sufficient to generate in vitro cytotoxicity.
4/2005Selective estrogen receptor modulators in the ruthenocene series. Synthesis and biological behavior.
11/2003Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines.
8/2003Tamoxifen derivatives for delivery of the antitumoral (DACH)Pt group: selective synthesis by McMurry coupling, and biochemical behaviour.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Gérard Jaouen Research Topics

Disease

32Breast Neoplasms (Breast Cancer)
05/2021 - 06/2003
22Neoplasms (Cancer)
04/2022 - 08/2003
6Melanoma (Melanoma, Malignant)
05/2021 - 09/2011
5Triple Negative Breast Neoplasms
11/2019 - 09/2013
4Glioblastoma (Glioblastoma Multiforme)
05/2021 - 09/2011
3Glioma (Gliomas)
08/2015 - 09/2008
3Prostatic Neoplasms (Prostate Cancer)
08/2009 - 03/2008
2Ovarian Neoplasms (Ovarian Cancer)
01/2018 - 10/2017
2Kidney Neoplasms (Kidney Cancer)
01/2018 - 12/2010
2Leukemia
09/2011 - 12/2010
2Experimental Melanoma
01/2011 - 02/2009
1Tuberculosis (Tuberculoses)
01/2020
1Brain Neoplasms (Brain Tumor)
11/2018
1Ovarian Epithelial Carcinoma
10/2017
1Hepatocellular Carcinoma (Hepatoma)
12/2015
1Colonic Neoplasms (Colon Cancer)
09/2011

Drug/Important Bio-Agent (IBA)

21Hormones (Hormone)IBA
06/2015 - 06/2003
15TamoxifenFDA LinkGeneric
01/2020 - 08/2003
13ferrocifenIBA
04/2022 - 12/2005
12Pharmaceutical PreparationsIBA
11/2018 - 04/2005
9NanocapsulesIBA
05/2021 - 01/2008
8LipidsIBA
05/2021 - 09/2008
7afimoxifene (hydroxytamoxifen)IBA
09/2013 - 08/2003
6Estrogens (Estrogen)FDA Link
06/2015 - 09/2004
6ferroceneIBA
11/2014 - 12/2005
6Estrogen Receptor alphaIBA
08/2010 - 11/2003
4Biological ProductsIBA
10/2020 - 01/2008
4hydroxide ionIBA
08/2015 - 06/2009
3Cisplatin (Platino)FDA LinkGeneric
01/2018 - 12/2010
3MetalsIBA
12/2017 - 01/2006
3Estrogen ReceptorsIBA
01/2011 - 01/2009
3ferrociphenolIBA
01/2010 - 01/2008
2ThioredoxinsIBA
01/2017 - 11/2014
2Alkenes (Olefins)IBA
09/2011 - 12/2010
2Estradiol (Delestrogen)FDA LinkGeneric
01/2011 - 11/2006
2butyleneIBA
08/2010 - 05/2006
2PolyphenolsIBA
08/2010 - 08/2009
2Selective Estrogen Receptor Modulators (SERM)IBA
09/2004 - 11/2003
2Estrogen Receptor Modulators (Antiestrogen)IBA
11/2003 - 08/2003
1Antiparasitic Agents (Antiparasitics)IBA
01/2020
1Sulfhydryl Compounds (Thiols)IBA
10/2019
1ProdrugsIBA
11/2018
1EstersIBA
11/2018
1RheniumIBA
07/2018
1Peptides (Polypeptides)IBA
07/2018
1MetallocenesIBA
08/2016
1Chloroquine (Aralen)FDA LinkGeneric
12/2015
1Coordination ComplexesIBA
12/2014
1PlatinumIBA
12/2014
11,1,2-triphenylbut-1-eneIBA
11/2014
1CaspasesIBA
11/2014
1DNA (Deoxyribonucleic Acid)IBA
11/2014
1PhosphatidylserinesIBA
11/2014
1Reactive Oxygen Species (Oxygen Radicals)IBA
06/2014
1VorinostatFDA Link
01/2014
1Organometallic CompoundsIBA
11/2013
1LuciferasesIBA
09/2013
1LigandsIBA
07/2012
1catechol (pyrocatechol)IBA
07/2012
1CatecholsIBA
07/2012
1auroneIBA
06/2012
1Human immunodeficiency virus 1 p31 integrase proteinIBA
10/2011
1Chalcone (Benzalacetophenone)IBA
10/2011
1TubulinIBA
01/2011
1Ether (Diethyl Ether)IBA
01/2011
1SolventsIBA
01/2011
1Estrogen Receptor betaIBA
08/2010
1Antineoplastic Agents (Antineoplastics)IBA
08/2010
1CarbonIBA
12/2009
1Phenol (Carbolic Acid)FDA Link
12/2009
12-oxindole (oxindole)IBA
02/2009
1SolutionsIBA
02/2009
1Phosphotransferases (Kinase)IBA
02/2009
13- ferrocenylmethylidene- 1,3- dihydro- 2H- indol- 2- oneIBA
02/2009
1Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
02/2009
1Drug CarriersIBA
09/2008
1MicellesIBA
09/2008
1monomethoxypolyethyleneglycol- polylactide block copolymerIBA
01/2008
1triphenylethyleneIBA
01/2008
1Protons (Proton)IBA
12/2005
1ruthenoceneIBA
04/2005
1RadiopharmaceuticalsIBA
04/2005
11,2-cyclohexanediamine (dach)IBA
08/2003

Therapy/Procedure

3Therapeutics
05/2021 - 12/2017
1Synchrotrons
11/2019
1Intravenous Injections
07/2018
1Drug Therapy (Chemotherapy)
01/2017
1Intraperitoneal Injections
09/2013
1Radiotherapy
01/2010
1Nanospheres
01/2008